RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Companyís product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCelís innovative technology, utilizing cell populations isolated from a patientís healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications.

Expert Comments:

Alphastox (2/12/17)
"RepliCel Life Sciences Inc.'s randomized, placebo-controlled trials in tendon and skin repair will deliver informative data to support the company's story, prioritize future clinical development and guide critical decisions about designing future multi-center clinical trials designed to provide statistically significant clinical data and address questions related to dosing, treatment frequency, etc. . .this is sure to be one of the most exciting stories of 2017 so make sure you stay tuned and keep a very close eye on RepliCel."

BioTuesdays (2/9/17)
"RepliCel Life Sciences Inc. announced the granting of two patents in Europe related to its multi-needle dermal injection technologies; the first patent has been validated in a total of 14 national countries and the second will also be validated in a number of European countries in the near future. The first device being developed under these patents, RCI-02, is designed for injecting hyaluronic acid and other products as dermal fillers."

"Back in 2013, before the Japanese regenerative medicine laws were promulgated, RepliCel Life Sciences Inc. and Shiseido signed a deal for Replicel's RCH-01 product, which is for androgenic alopecia or male pattern baldness. Shiseido is taking the RCH-01 product down the Act on the Safety of Regenerative Medicine (ASRM) route to market, as they see immense market potential to offer the treatment as quickly as possible to men who suffer from pattern baldness. The ASRM route to market does not come with the coveted Japanese NHI insurance coverage, but the indication is one that doesnít necessarily need the NHI insurance coverage incentive to work. Shiseido already has opened the Shiseido Cell-Processing and Expansion Center (SPEC) in Kobe and is using this location as its base to develop and eventually provide the therapy. Not many non-Japanese companies understand the ASRM route to market but it is one that a relatively well-known regenerative medicine company, Cytori Therapeutics, has already received multiple approvals for over the years and is a very real and relatively fast route to market that exists in Japan. I would keep my eyes peeled on RepliCel and Shiseido in the coming months too for indications as to when the therapy will become available in Japan." read more >

Zacks Equity Research (1/24/17)
"One company that looks very well-positioned to benefit from regenerative medicine's rising tide is RepliCel Life Sciences Inc. . .RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. . .the company's current focus is on the repair of chronically injured tendons, restoration of damaged skin, and the rejuvenation of hair growth.RepliCel is currently engaged in a Phase 1/2 clinical study taking place in Canada examining RCT-01 for the treatment of chronic tendinosis."

Alphastox.com (1/22/17)
"We've been wildly successful with a couple of our biotech picks, including RepliCel Life Sciences Inc., which is up over 250% in just three months! The company is just starting to get going and I feel we have a ton more room to grow in this deal."

Douglas Loe, Echelon Growth Partners (11/2/16)
"RepliCel Life Sciences Inc. reported T4W returns of +49% after announcing the close of the firmís $4.3M private placement. . .performance observed is not just that data point alone; RepliCel is nearing clinical milestones in H216 and H117, specifically with the firmís 10-patient Phase I/II trial, evaluating the autologous non-bulbar dermal sheath cell therapy RCT-01 in patients with Achilles tendinosis. Data from this trial is expected by end of this year. . .a 17-patient skin rejuvenation Phase I/II trial in Germany could release interim sixmonth RCS-01 efficacy data by FQ117."

More Expert Comments

Experts Following This Company

Douglas Loe, Analyst – Euro Pacific Canada
Colin Lee Novick, Managing Director – CJ PARTNERS
Eden Rahim, Portfolio Manager and Options Strategist – Next Edge Capital, Theta Strategies Capital

The information provided above is from analysts, newsletters, the company and other contributors.

RepliCel Life Sciences Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Data announcements from 3 different clinical trials in Q1 2017
Biotech company focused on large aesthetic and sports injury markets
Small-cap biotech company expected to be generating revenue in 2018
catalyst Calendar